TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22773769
Drug: No patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: No patch (control period)
Study: 15093987
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg od
Study: 11399783
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg) three times daily for 7 days
Study: 11399783
Drug: Chitosan (890
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan (890 mg) three times daily for 7 days
Study: 9257889
Drug: HD‐CY (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD‐CY (4 g/m2 i.v.) plus GM‐CSF (8 microg/kg/day s.c.)
Study: 9257889
Drug: G‐CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (10 microg/kg/day s.c.) alone
Study: 9678793
Drug: G‐CSF alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF alone
Study: 31420414
Drug: Pertuzumab (840→420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab (840→420 mg every 3 weeks)
Study: 25795927
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (CBT) for perfectionism
Study: 21875697
Drug: Subinguinal varicocelectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subinguinal varicocelectomy after 2 ml intratunical space injection of methylene blue
Study: 19701034
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment (scaling and root planing early in the second trimester)
Study: 19701034
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (periodontal care after delivery)
Study: 11422091
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg qd lanepitant
Study: 8637697
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection at 37 degrees C (body temperature)
Study: 6378437
Drug: Indomethacin, 25
Normalized name: Indomethacin, 25 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 25 mg tds
Study: 6378437
Drug: Aspirin-SR, 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-SR, 650 mg daily
Study: 6378437
Drug: Paracetamol, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol, 1 g 8th hourly
Study: 6378437
Drug: Naproxen, 250
Normalized name: Naproxen, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen, 250 mg mane and 500 mg nocte
Study: 6378437
Drug: Sulindac, 200
Normalized name: Sulindac, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac, 200 mg bd
Study: 24722423
Drug: Jinzhen oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinzhen oral liquid
Study: 23379201
Drug: Olopatadine 0.2%
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine 0.2% (instilled twice-daily)
Study: 23379201
Drug: Olopatadine 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 0.1% (instilled 4-times daily)
Study: 20199178
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg three times a day (Group 1)
Study: 20199178
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg and pentoxifylline 400 mg each three times per day (Group 2)
Study: 11849194
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of 1 g paracetamol
Study: 11849194
Drug: Tablets of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of paracetamol
Study: 7737532
Drug: Spectrotypic analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectrotypic analysis of antibody response
Study: 30950565
Drug: GSK3008356 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3008356 single doses (5 to 200 mg)
Study: 30950565
Drug: GSK3008356 repeat
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3008356 repeat doses (1, 3, and 10 mg twice daily for 14 days)
Study: 30950565
Drug: GSK3008356 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3008356 single doses
Study: 30950565
Drug: GSK3008356 repeat
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3008356 repeat doses
Study: 30950565
Drug: GSK3008356 higher
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3008356 higher doses
Study: 27092862
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy (CT) plus treatment as usual (TAU)
Study: 19735515
Drug: Hydrating gel-cream
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrating gel-cream (active product)
Study: 19735515
Drug: Gel-cream without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel-cream without active substances (placebo)
Study: 17317205
Drug: Pegfilgrastim (6mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (6mg single dose on day 2 of FEC-100) - Primary Prophylaxis (PP)
Study: 17317205
Drug: Pegfilgrastim (6mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (6mg single dose on day 2 of FEC-100) - Secondary Prophylaxis (SP)
Study: 9815633
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate (PPS) administered orally (p.o.) at doses of 180, 270, and 400 mg/m2 t.i.d.
Study: 9815633
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate (PPS) administered orally (p.o.) at doses of 400 mg/m2 t.i.d.
Study: 9815633
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate (PPS) administered orally (p.o.) at various doses.
Study: 8230266
Drug: Tamoxifen 40
Normalized name: tamoxifen 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 40 mg/d orally for 2 years
Study: 2439786
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg bisoprolol
Study: 29939421
Drug: Euglycaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemic clamp (5-6 mmol/l)
Study: 29939421
Drug: Hyperglycaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemic clamp (9-10 mmol/l)
Study: 26214555
Drug: Fluvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (10 mg daily)
Study: 26214555
Drug: Valsartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (20 mg daily)
Study: 26214555
Drug: Fluvastatin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin and Valsartan combination (10 mg and 20 mg)
Study: 20046171
Drug: Ultrasonic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic therapy (UST)
Study: 3613693
Drug: Sulpiride 200
Normalized name: sulpiride 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 200 mg
Study: 15107193
Drug: Sulpiride 400
Normalized name: sulpiride 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 400 mg
Study: 12421850
Drug: [6S]-5-methyltetrahydrofolate (113
Approvals — FDA: no, EMA: no, PMDA: no
Description: [6S]-5-methyltetrahydrofolate (113 micro g/d)
Study: 12421850
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (100 micro g/d)
Study: 10604083
Drug: Treatment responders
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment responders (n=21)
Study: 25834203
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab (TCZ‐SC) monotherapy, 162 mg every 2 weeks (q2w)
Study: 25834203
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab (TCZ‐SC) monotherapy
Study: 25834203
Drug: Intravenous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous tocilizumab (TCZ‐IV) monotherapy, 8 mg/kg every 4 weeks
Study: 22471559
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg daily
Study: 26510725
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg daily
Study: 12774231
Drug: Four tasks
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four tasks resulting from a factorial combination of two types of judgment and two judgment-to-response mappings
Study: 11361054
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg for 24 days with simvastatin 40 mg on Days 15-24
Study: 11361054
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg for 10 days
Study: 11361054
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg for 24 days with simvastatin 80 mg on Days 15-24
Study: 11361054
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg for 10 days
Study: 9624541
Drug: Enoxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin (400 mg)
Study: 8792486
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg)
Study: 8033544
Drug: 1% SLG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% SLG solution
Study: 8033544
Drug: 1% surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% surfactant mixture solutions (M1, M2, M3)
Study: 8033544
Drug: 1% SLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% SLS solution
Study: 21443416
Drug: Probiotic fermented
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic fermented milk (500 ml daily containing at least 5 × 10(7) CFU/ml of Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5, and Bifidobacterium lactis Bb12)
Study: 16611288
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol 4000 (0.50 g/kg)
Study: 16611288
Drug: Lactulose (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (1.5 g/kg)
Study: 2220725
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg qid)
Study: 26588357
Drug: Implant placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant placement (IMP)
Study: 15125846
Drug: Single caudal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single caudal epidural injection of 20 ml containing bupivacaine and tramadol
Study: 15125846
Drug: Single caudal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single caudal epidural injection of 20 ml of normal saline
Study: 9856165
Drug: Withholding albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding albumin or administration of crystalloid fluids
Study: 24731899
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) for headache pain management, 8-week duration
Study: 23727917
Drug: Dexmedetomidine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 3 µg
Study: 9502454
Drug: piperacillin-tazobactam (TAZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperacillin-tazobactam (TAZ; 4 g/0.5 g q.i.d.) + amikacin (7.5 mg/kg b.i.d.)
Study: 9502454
Drug: ceftazidime (CAZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftazidime (CAZ; 1 g q.i.d.) + amikacin (7.5 mg/kg b.i.d.)
Study: 8310997
Drug: Yogurt enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yogurt enriched with Bifidobacterium longum and 5 g lactulose/L (A)
Study: 3402355
Drug: urapidil 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: urapidil 120 mg once daily
Study: 3402355
Drug: urapidil 60
Normalized name: urapidil 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: urapidil 60 mg twice daily
Study: 25335248
Drug: Scraping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scraping therapy (44 cases)
Study: 25335248
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (41 cases)
Study: 25335248
Drug: Both scraping
Normalized name: Sarapin
DrugBank: Sarracenia Purpurea (DB13965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both scraping and acupuncture therapies
Study: 25335248
Drug: Scraping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scraping therapy
Study: 20631341
Drug: 3B(90)E(500)P (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3B(90)E(500)P (30 kU bleomycin on days 1, 8, and 15; 100 mg/m(2) etoposide on days 1‐5; 20 mg/m(2) cisplatin on days 1‐5; n = 83)
Study: 20631341
Drug: 4B(30)E(360)P (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4B(30)E(360)P (30 kU bleomycin on day 1; 120 mg/m(2) etoposide on days 1‐3; 100 mg/m(2) cisplatin on day 1; n = 83)
Study: 16804655
Drug: Piperacillin/tazobactam (P/T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (P/T) at 4 g/0.5 g
Study: 16804655
Drug: Imipenem/cilastatin (I/C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (I/C) at 1 g/1 g
Study: 11544831
Drug: Endolymphic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endolymphic infusion of immunomodulator
Study: 11544831
Drug: Regional infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regional infusion of considerable doses of cytostatic mixes
Study: 31418585
Drug: Abaloparatide 80
Normalized name: ABALOPARATIDE 80MCG/0.04ML PEN 1.56ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide 80 µg daily
Study: 31418585
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 µg daily
Study: 26242335
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with an exercise program
Study: 2944534
Drug: Ethinyloestradiol 50
Normalized name: Ethinyloestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyloestradiol 50 micrograms/cyproterone acetate 50 mg
Study: 30770539
Drug: Slightly sweet
Normalized name: Oracoat Xylimelts Dry Mouth Slightly Sweet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slightly sweet lipid-based nutrient supplement (LNS)
Study: 26097440
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.4 g · kg(‐1) body weight)
Study: 19139776
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (n=27) received 15 ml (102.5mg) of 0.75% solution
Study: 19139776
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (n=27) received 10 ml (75 mg) of 0.75% solution
Study: 19139776
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (n=27) received 10 ml (50mg) 0.5% ropivacaine
Study: 18232268
Drug: Iodised salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodised salt plus weekly 70 mg iron supplement (IS + iron)
Study: 18232268
Drug: Iodised salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodised salt (IS) plus weekly placebo (control group)
Study: 15111940
Drug: Physical methods,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical methods, especially with the use of biological feedback
Study: 15111940
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pharmacological and physical treatments
Study: 9741655
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide (HBB) 10 mg
Study: 9741655
Drug: Atropine sulphate
Normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulphate 0.4 mg
Study: 30864532
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment alternative to hospital care (experimental group)
Study: 30864532
Drug: Conventional service
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional service model without home treatment (control group)
Study: 28632865
Drug: Cetuximab combined
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab combined with mFOLFOX6 or FOLFIRI chemotherapy
Study: 28632865
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with mFOLFOX6 or FOLFIRI chemotherapy
Study: 17304888
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical application
Study: 17031654
Drug: Sequential ureteric
Normalized name: Bos taurus ureter preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential ureteric catheter insertion
Study: 10077720
Drug: Bioresonance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioresonance therapy (10 sessions)
Study: 10077720
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy (after bioresonance therapy)
Study: 10077720
Drug: Bioresonance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioresonance therapy (after speech therapy)
Study: 7740939
Drug: Half‐thickness patellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half‐thickness patellar tendon graft augmented with the Kennedy Ligament Augmentation Device (LAD)
Study: 2184133
Drug: Disulfiram 100
Normalized name: disulfiram 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 100 mg
Study: 2184133
Drug: Disulfiram 400
Normalized name: disulfiram 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 400 mg
Study: 21703848
Drug: Preoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative treatment according to the localised-disease protocol
Study: 21703848
Drug: Preoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative treatment according to the metastatic-disease protocol
Study: 19829096
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 international units daily for 12 weeks)
Study: 16249540
Drug: Ruboxistaurin 32
Normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruboxistaurin 32 mg/day for 1 year
Study: 8703664
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg daily for 15 days
Study: 29243058
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ondansetron IV (group O)
Study: 29243058
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml saline (group S)
Study: 10791526
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment schedule (10 daily injections of 2.2 mg/kg)
Study: 10791526
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment schedule (26-day regimen of melarsoprol with doses increasing from 1.2 to 3.6 mg/kg)
Study: 9289940
Drug: Tensiomin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tensiomin (50 mg)
Study: 9289940
Drug: Tensiomin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tensiomin (100 mg)
Study: 9289940
Drug: Capoten (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capoten (50 mg)
Study: 9289940
Drug: Capoten (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capoten (100 mg)
Study: 9289940
Drug: Lopirin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopirin (50 mg)
Study: 3602016
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily regimen of combined inhalation of salbutamol and beclomethasone dipropionate from a single inhaler
Study: 3602016
Drug: 4-times daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-times daily regimen of combined inhalation of salbutamol and beclomethasone dipropionate from a single inhaler
Study: 30514741
Drug: Hill's Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hill's Prescription Diet k/d Feline with chicken, dry
Study: 27645692
Drug: Metabolic tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolic tumor volume (MTV) pre-treatment >32 mL
Study: 27645692
Drug: Higher tMTV-pre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher tMTV-pre (per 10-mL increase)
Study: 27645692
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose (≤60 Gy vs. 61-69 Gy or ≥70 Gy) in patients with tMTV-pre >32 mL
Study: 27645692
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose in patients with tMTV-pre ≤32 mL
Study: 14501447
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (Prednisone 60mg and taper)
Study: 28503770
Drug: Intravenous levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous levetiracetam (LEVIV) 20 mg/kg
Study: 28503770
Drug: Intranasal crushed
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal crushed immediate release levetiracetam (LEVCIR) 30 mg/kg